Oculopharyngeal Muscular Dystrophy (OPMD) Market - Regional Analysis
North American Market Insights
The North America industry is poised to hold largest revenue share of 36% by 2035. The growth of the market can be attributed to the growing frequency of Oculopharyngeal muscular dystrophy disorder in the region. For instance, the highest prevalence rate of Oculopharyngeal muscular dystrophy 1/1000 people can be found in French Canadian population of Quebec Canada. In USA around 1/100,000 people are diagnosed with Oculopharyngeal muscular dystrophy. Furthermore, high health awareness among the population along with easy access to quality healthcare in developed region is attributed to rapid market expansion in the region during the forecast period. In addition to that, the region’s rising technological healthcare industry and expanding expenditure are also anticipated to boost the market growth in the upcoming years.
APAC Market Insights
The Asia Pacific oculopharyngeal muscular dystrophy market is estimated to the second largest, revenue share of about 29% by the end of 2035. The market’s expansion can be attributed majorly to the soaring prevalence of different chronic diseases and prolonged pain, ache and infection among the people living in the region. According to studies across Asia, the prevalence of chronic pain in adults has been reported to vary greatly, ranging from 7% in Malaysia to 60% in Cambodia and Northern Iraq. Older adults are more likely to experience chronic pain, with prevalence rates as high as 40% to 90%. Additionally, the rising focus on health and fitness coupled with government initiatives which promote a healthy lifestyle is anticipated to increase the adoption rate of Oculopharyngeal muscular dystrophy. These factors are estimated to expand the market size in the forecast period.
